{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T15:40:32Z","timestamp":1767973232456,"version":"3.49.0"},"reference-count":88,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T00:00:00Z","timestamp":1724284800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.lpm.2024.104242","type":"journal-article","created":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T11:50:43Z","timestamp":1725709843000},"page":"104242","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Preventative and curative treatment of venous thromboembolic disease in cancer patients"],"prefix":"10.1016","volume":"53","author":[{"given":"Marc","family":"Carrier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Bertoletti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Girard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvie","family":"Laporte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Mah\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.lpm.2024.104242_bib0001","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/archinte.160.6.761","article-title":"Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study","volume":"160","author":"Heit","year":"2000","journal-title":"Arch Intern Med"},{"issue":"14","key":"10.1016\/j.lpm.2024.104242_bib0002","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1182\/blood.2020007338","article-title":"Venous thromboembolism in cancer patients: a population-based cohort study","volume":"137","author":"Mulder","year":"2021","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.lpm.2024.104242_bib0003","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1182\/blood-2013-04-460121","article-title":"Epidemiology of cancer-associated venous thrombosis","volume":"122","author":"Timp","year":"2013","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.lpm.2024.104242_bib0004","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","article-title":"Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy","volume":"5","author":"Khorana","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"9","key":"10.1016\/j.lpm.2024.104242_bib0005","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1007\/s00520-018-4174-5","article-title":"Patients' experience of living with cancer-associated thrombosis in Spain (PELICANOS)","volume":"26","author":"Font","year":"2018","journal-title":"Support Care Cancer"},{"issue":"4","key":"10.1016\/j.lpm.2024.104242_bib0006","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jval.2017.09.015","article-title":"What impact does venous thromboembolism and bleeding have on cancer patients' quality of life?","volume":"21","author":"Lloyd","year":"2018","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.lpm.2024.104242_bib0007","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/rth2.12274","article-title":"Patient experience of living with cancer-associated thrombosis in Canada (PELICANADA)","volume":"4","author":"Noble","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.lpm.2024.104242_bib0008","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2147\/PPA.S79373","article-title":"Patients' Experiences of LIving with CANcer-associated thrombosis: the PELICAN study","volume":"9","author":"Noble","year":"2015","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.lpm.2024.104242_bib0009","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1007\/BF01377122","article-title":"Treatment with coumarin to prevent or delay recurrence of malignant melanoma","volume":"120","author":"Thornes","year":"1994","journal-title":"J Cancer Res Clin Oncol"},{"issue":"9","key":"10.1016\/j.lpm.2024.104242_bib0010","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1046\/j.1538-7836.2003.00341.x","article-title":"Antimetastatic effect of tinzaparin, a low-molecular-weight heparin","volume":"1","author":"Amirkhosravi","year":"2003","journal-title":"J Thromb Haemost"},{"issue":"7","key":"10.1016\/j.lpm.2024.104242_bib0011","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1055\/s-2007-991536","article-title":"Heparin in tumor progression and metastatic dissemination","volume":"33","author":"Falanga","year":"2007","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.lpm.2024.104242_bib0012","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.thromres.2020.07.008","article-title":"A systematic review on the efficacy and safety of low molecular weight heparin as an anticancer therapeutic in preclinical animal models","volume":"195","author":"Ripsman","year":"2020","journal-title":"Thromb Res"},{"issue":"4","key":"10.1016\/j.lpm.2024.104242_bib0013","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/j.1538-7836.2007.02427.x","article-title":"The effect of low-molecular-weight heparin on cancer survival. A systematic review and meta-analysis of randomized trials","volume":"5","author":"Lazo-Langner","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"5","key":"10.1016\/j.lpm.2024.104242_bib0014","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1055\/s-0040-1709712","article-title":"The efficacy and safety of low molecular weight heparin administration to improve survival of cancer patients: a systematic review and meta-analysis","volume":"120","author":"Montroy","year":"2020","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.lpm.2024.104242_bib0015","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jclinepi.2020.04.006","article-title":"Early detection of the existence or absence of the treatment effect: a cumulative meta-analysis","volume":"124","author":"Laporte","year":"2020","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.lpm.2024.104242_bib0016","article-title":"Efficacy and safety of extended duration to perioperative thromboprophylaxis with low molecular weight heparin on disease-free survival after surgical resection of colorectal cancer (PERIOP-01): multicentre, open label, randomised controlled trial","volume":"378","author":"Auer","year":"2022","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.lpm.2024.104242_bib0017","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/s41416-019-0533-3","article-title":"Randomised phase 3 study of adjuvant chemotherapy with or without nadroparin in patients with completely resected non-small-cell lung cancer: the NVALT-8 study","volume":"121","author":"Groen","year":"2019","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.lpm.2024.104242_bib0018","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01220-2018","article-title":"Anti-tumour effect of low molecular weight heparin in localised lung cancer: a phase III clinical trial","volume":"52","author":"Meyer","year":"2018","journal-title":"Eur Respir J"},{"issue":"7","key":"10.1016\/j.lpm.2024.104242_bib0019","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa1108898","article-title":"Investigators S-O. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer","volume":"366","author":"Agnelli","year":"2012","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.lpm.2024.104242_bib0020","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S1470-2045(09)70232-3","article-title":"Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study","volume":"10","author":"Agnelli","year":"2009","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.lpm.2024.104242_bib0021","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1177\/1076029611433769","article-title":"Investigators T. Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III\/IV lung cancer","volume":"18","author":"Haas","year":"2012","journal-title":"Clin Appl Thromb Hemost"},{"issue":"9","key":"10.1016\/j.lpm.2024.104242_bib0022","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.ejca.2011.10.017","article-title":"Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer","volume":"48","author":"Maraveyas","year":"2012","journal-title":"Eur J Cancer"},{"issue":"18","key":"10.1016\/j.lpm.2024.104242_bib0023","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1200\/JCO.2014.55.1481","article-title":"Efficacy of prophylactic low-molecular weight heparin for ambulatory patients with advanced pancreatic cancer: outcomes from the CONKO-004 trial","volume":"33","author":"Pelzer","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lpm.2024.104242_bib0024","article-title":"Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy","volume":"12","author":"Di Nisio","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1016\/j.lpm.2024.104242_bib0025","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update","volume":"38","author":"Key","year":"2020","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.lpm.2024.104242_bib0026","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","article-title":"American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer","volume":"5","author":"Lyman","year":"2021","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.lpm.2024.104242_bib0027","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1182\/blood-2008-02-142422","article-title":"High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS)","volume":"112","author":"Ay","year":"2008","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.lpm.2024.104242_bib0028","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1634\/theoncologist.2016-0246","article-title":"Preventing venous thromboembolism in ambulatory cancer patients: the ONKOTEV study","volume":"22","author":"Cella","year":"2017","journal-title":"Oncologist"},{"issue":"10","key":"10.1016\/j.lpm.2024.104242_bib0029","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1634\/theoncologist.2016-0414","article-title":"A predictive score for thrombosis associated with breast, colorectal, lung, or ovarian cancer: the prospective COMPASS-cancer-associated thrombosis study","volume":"22","author":"Gerotziafas","year":"2017","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.lpm.2024.104242_bib0030","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/jth.12778","article-title":"Factor V Leiden mutation increases the risk for venous thromboembolism in cancer patients - results from the Vienna Cancer And Thrombosis Study (CATS)","volume":"13","author":"Pabinger","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"3","key":"10.1016\/j.lpm.2024.104242_bib0031","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s11739-012-0784-y","article-title":"A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score","volume":"7","author":"Verso","year":"2012","journal-title":"Intern Emerg Med"},{"issue":"8","key":"10.1016\/j.lpm.2024.104242_bib0032","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/s41416-018-0027-8","article-title":"Multivariable clinical-genetic risk model for predicting venous thromboembolic events in patients with cancer","volume":"118","author":"Munoz Martin","year":"2018","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.lpm.2024.104242_bib0033","doi-asserted-by":"crossref","first-page":"e303","DOI":"10.1055\/s-0041-1729626","article-title":"Predictive ability of a clinical-genetic risk score for venous thromboembolism in northern and southern European populations","volume":"5","author":"Salas","year":"2021","journal-title":"TH Open"},{"issue":"5","key":"10.1016\/j.lpm.2024.104242_bib0034","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.annonc.2022.12.014","article-title":"clinicalguidelines@esmo.org EGCEa. Venous thromboembolism in cancer patients: ESMO clinical practice guideline","volume":"34","author":"Falanga","year":"2023","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.lpm.2024.104242_bib0035","doi-asserted-by":"crossref","first-page":"e566","DOI":"10.1016\/S1470-2045(19)30336-5","article-title":"International Initiative on T, Cancer advisory p. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer","volume":"20","author":"Farge","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.lpm.2024.104242_bib0036","unstructured":"Guidelines: https:\/\/www.nccn.org\/professionals\/physician_gls\/default.aspx#supportive. [Internet]. [cited March 28, 2020]."},{"issue":"10","key":"10.1016\/j.lpm.2024.104242_bib0037","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1111\/jth.14564","article-title":"The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: guidance from the SSC of the ISTH","volume":"17","author":"Wang","year":"2019","journal-title":"J Thromb Haemost"},{"issue":"5","key":"10.1016\/j.lpm.2024.104242_bib0038","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/bjh.13556","article-title":"Guideline on aspects of cancer-related venous thrombosis","volume":"170","author":"Watson","year":"2015","journal-title":"Br J Haematol"},{"issue":"Suppl 1","key":"10.1016\/j.lpm.2024.104242_bib0039","first-page":"S82","article-title":"Cancer and coagulation","volume":"87","author":"Khorana","year":"2012","journal-title":"Am J Hematol"},{"issue":"24","key":"10.1016\/j.lpm.2024.104242_bib0040","doi-asserted-by":"crossref","first-page":"5377","DOI":"10.1182\/blood-2010-02-270116","article-title":"Prediction of venous thromboembolism in cancer patients","volume":"116","author":"Ay","year":"2010","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.lpm.2024.104242_bib0041","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.3324\/haematol.2018.209114","article-title":"The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis","volume":"104","author":"Mulder","year":"2019","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.lpm.2024.104242_bib0042","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1001\/jamaoncol.2023.3625","article-title":"Prevalence of thromboembolic events in patients with non-small cell lung cancer and RET fusions","volume":"9","author":"Aldea","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.lpm.2024.104242_bib0043","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.thromres.2017.01.009","article-title":"Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: a randomized trial","volume":"151","author":"Khorana","year":"2017","journal-title":"Thromb Res"},{"issue":"8","key":"10.1016\/j.lpm.2024.104242_bib0044","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1111\/jth.14824","article-title":"The Khorana score for prediction of venous thromboembolism in cancer patients: an individual patient data meta-analysis","volume":"18","author":"van Es","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"8","key":"10.1016\/j.lpm.2024.104242_bib0045","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJMoa1814630","article-title":"Investigators C. Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer","volume":"380","author":"Khorana","year":"2019","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.lpm.2024.104242_bib0046","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"Investigators A. Apixaban to prevent venous thromboembolism in patients with cancer","volume":"380","author":"Carrier","year":"2019","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.lpm.2024.104242_bib0047","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1056\/NEJMe1816060","article-title":"Direct oral anticoagulants for thromboprophylaxis in ambulatory patients with cancer","volume":"380","author":"Agnelli","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.lpm.2024.104242_bib0048","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1002\/onco.13569","article-title":"Prediction and prevention of cancer-associated thromboembolism","volume":"26","author":"Khorana","year":"2021","journal-title":"Oncologist"},{"issue":"40","key":"10.1016\/j.lpm.2024.104242_bib0049","doi-asserted-by":"crossref","first-page":"E1551","DOI":"10.1503\/cmaj.210523","article-title":"Cost-utility analysis of apixaban compared with usual care for primary thromboprophylaxis in ambulatory patients with cancer","volume":"193","author":"Kimpton","year":"2021","journal-title":"CMAJ"},{"issue":"8","key":"10.1016\/j.lpm.2024.104242_bib0050","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1002\/cncr.32724","article-title":"Cost-effectiveness analysis of low-dose direct oral anticoagulant (DOAC) for the prevention of cancer-associated thrombosis in the United States","volume":"126","author":"Li","year":"2020","journal-title":"Cancer"},{"issue":"20","key":"10.1016\/j.lpm.2024.104242_bib0051","doi-asserted-by":"crossref","first-page":"5215","DOI":"10.1182\/bloodadvances.2020003115","article-title":"Primary thromboprophylaxis in ambulatory cancer patients with a high Khorana score: a systematic review and meta-analysis","volume":"4","author":"Bosch","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.lpm.2024.104242_bib0052","unstructured":"Centres AoCC. Venous thromboembolism: identifying cancer patients at risk. 2016. Available from: https:\/\/www.accc-cancer.org\/docs\/projects\/resources\/pdf\/vte-identifying-cancer-patients-at-risk-2016."},{"issue":"9","key":"10.1016\/j.lpm.2024.104242_bib0053","doi-asserted-by":"crossref","first-page":"e868","DOI":"10.1200\/JOP.19.00697","article-title":"Successful model for guideline implementation to prevent cancer-associated thrombosis: venous thromboembolism prevention in the ambulatory cancer clinic","volume":"16","author":"Holmes","year":"2020","journal-title":"JCO Oncol Pract"},{"issue":"15","key":"10.1016\/j.lpm.2024.104242_bib0054","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/archinte.162.15.1729","article-title":"Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study","volume":"162","author":"Meyer","year":"2002","journal-title":"Arch Intern Med"},{"issue":"2","key":"10.1016\/j.lpm.2024.104242_bib0055","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","volume":"349","author":"Lee","year":"2003","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.lpm.2024.104242_bib0056","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.ejvs.2018.11.004","article-title":"Editor's choice - a systematic review and meta-analysis of the efficacy and safety of anticoagulation in the treatment of venous thromboembolism in patients with cancer","volume":"57","author":"Kirkilesis","year":"2019","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"6","key":"10.1016\/j.lpm.2024.104242_bib0057","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jaccao.2023.09.003","article-title":"Cancer-associated thrombosis: trends in clinical features, treatment, and outcomes from 2001 to 2020","volume":"5","author":"Bertoletti","year":"2023","journal-title":"JACC CardioOncol"},{"issue":"1","key":"10.1016\/j.lpm.2024.104242_bib0058","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/rth2.12002","article-title":"Current practice patterns and patient persistence with anticoagulant treatments for cancer-associated thrombosis","volume":"1","author":"Khorana","year":"2017","journal-title":"Res Pract Thromb Haemost"},{"issue":"12","key":"10.1016\/j.lpm.2024.104242_bib0059","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1182\/blood-2014-04-571232","article-title":"Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials","volume":"124","author":"van Es","year":"2014","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.lpm.2024.104242_bib0060","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.lpm.2024.104242_bib0061","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.lpm.2024.104242_bib0062","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/jth.14662","article-title":"Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial","volume":"18","author":"McBane","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"17","key":"10.1016\/j.lpm.2024.104242_bib0063","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.lpm.2024.104242_bib0064","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.chest.2021.09.037","article-title":"Rivaroxaban vs dalteparin in cancer-associated thromboembolism: a randomized trial","volume":"161","author":"Planquette","year":"2022","journal-title":"Chest"},{"issue":"22","key":"10.1016\/j.lpm.2024.104242_bib0065","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2023.7843","article-title":"Direct oral anticoagulants vs low-molecular-weight heparin and recurrent VTE in patients with cancer: a randomized clinical trial","volume":"329","author":"Schrag","year":"2023","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.lpm.2024.104242_bib0066","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13045-022-01289-1","article-title":"Direct oral anticoagulant versus low molecular weight heparin for the treatment of cancer-associated venous thromboembolism: 2022 updated systematic review and meta-analysis of randomized controlled trials","volume":"15","author":"Frere","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"8","key":"10.1016\/j.lpm.2024.104242_bib0067","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1055\/s-0038-1667001","article-title":"Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the hokusai VTE Cancer Study","volume":"118","author":"Kraaijpoel","year":"2018","journal-title":"thromb haemost"},{"issue":"4","key":"10.1016\/j.lpm.2024.104242_bib0068","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/rth2.12359","article-title":"Direct oral anticoagulants compared to low-molecular-weight heparin for the treatment of cancer-associated thrombosis: updated systematic review and meta-analysis of randomized controlled trials","volume":"4","author":"Moik","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"issue":"7","key":"10.1016\/j.lpm.2024.104242_bib0069","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1055\/s-0040-1712098","article-title":"Direct oral anticoagulants for the treatment of acute venous thromboembolism associated with cancer: a systematic review and meta-analysis","volume":"120","author":"Giustozzi","year":"2020","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.lpm.2024.104242_bib0070","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.thromres.2023.10.004","article-title":"The prevalence of relevant drug-drug interactions and associated clinical outcomes in patients with cancer-associated thrombosis on concurrent anticoagulation and anticancer or supportive care therapies","volume":"231","author":"Wang","year":"2023","journal-title":"Thromb Res"},{"issue":"8","key":"10.1016\/j.lpm.2024.104242_bib0071","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1111\/jth.15367","article-title":"Characteristics and outcomes of patients on concurrent direct oral anticoagulants and targeted anticancer therapies-TacDOAC registry: communication from the ISTH SSC Subcommittee on Hemostasis and Malignancy","volume":"19","author":"Wang","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.lpm.2024.104242_bib0072","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103599","article-title":"Practical treatment guidance for cancer-associated thrombosis - managing the challenging patient: a consensus statement","volume":"171","author":"Musgrave","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"issue":"Suppl 1","key":"10.1016\/j.lpm.2024.104242_bib0073","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1016\/j.thromres.2021.11.026","article-title":"Drug-drug interactions: implications for anticoagulation, with focus in patients with cancer","volume":"213","author":"Wang","year":"2022","journal-title":"Thromb Res"},{"key":"10.1016\/j.lpm.2024.104242_bib0074","article-title":"Cancer-associated thrombosis: how many patients seen in clinical practice would be eligible for a direct oral anticoagulant randomized controlled trial?","volume":"85","author":"Petit","year":"2023","journal-title":"Respir Med Res"},{"issue":"22","key":"10.1016\/j.lpm.2024.104242_bib0075","doi-asserted-by":"crossref","first-page":"4741","DOI":"10.1182\/bloodadvances.2021005116","article-title":"Polyphosphate expression by cancer cell extracellular vesicles mediates binding of factor XII and contact activation","volume":"5","author":"Shim","year":"2021","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.lpm.2024.104242_bib0076","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1093\/oncolo\/oyad116","article-title":"Treatment of cancer-associated thrombosis: recent advances, unmet needs, and future direction","volume":"28","author":"Wang","year":"2023","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.lpm.2024.104242_bib0077","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1055\/a-1384-3715","article-title":"Factor XI as a target for new anticoagulants","volume":"41","author":"Fredenburgh","year":"2021","journal-title":"Hamostaseologie"},{"issue":"2","key":"10.1016\/j.lpm.2024.104242_bib0078","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/jth.15577","article-title":"Pharmacokinetics and pharmacodynamics of abelacimab (MAA868), a novel dual inhibitor of Factor XI and Factor XIa","volume":"20","author":"Yi","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"6","key":"10.1016\/j.lpm.2024.104242_bib0079","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.jacc.2021.06.010","article-title":"Factor XI inhibition to uncouple thrombosis from hemostasis: JACC review topic of the week","volume":"78","author":"Hsu","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.lpm.2024.104242_bib0080","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/jth.15579","article-title":"A proposal for managing bleeding in patients on therapeutic factor XI(a) inhibitors","volume":"20","author":"Salomon","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"11","key":"10.1016\/j.lpm.2024.104242_bib0081","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1111\/jth.14561","article-title":"Extended treatment with edoxaban in cancer patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE cancer study","volume":"17","author":"Di Nisio","year":"2019","journal-title":"J Thromb Haemost"},{"issue":"6","key":"10.1016\/j.lpm.2024.104242_bib0082","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/jth.12923","article-title":"Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN study","volume":"13","author":"Francis","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.lpm.2024.104242_bib0083","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.thromres.2017.07.004","article-title":"Tinzaparin in cancer associated thrombosis beyond 6months: TiCAT study","volume":"157","author":"Jara-Palomares","year":"2017","journal-title":"Thromb Res."},{"issue":"8","key":"10.1016\/j.lpm.2024.104242_bib0084","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1111\/jth.15760","article-title":"Step down to 6 months of prophylactic-dose low molecular weight heparin after initial full-dose anticoagulation for the treatment of cancer-associated thrombosis (STEP-CAT): a pilot study","volume":"20","author":"Popov","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"5","key":"10.1016\/j.lpm.2024.104242_bib0085","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1111\/jth.15666","article-title":"Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients - 30 months follow-up","volume":"20","author":"Larsen","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"4","key":"10.1016\/j.lpm.2024.104242_bib0086","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/jth.14752","article-title":"Treatment of cancer-associated venous thromboembolism: 12-month outcomes of the placebo versus rivaroxaban randomization of the SELECT-D Trial (SELECT-D: 12m)","volume":"18","author":"Marshall","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.lpm.2024.104242_bib0087","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtha.2024.03.011","article-title":"Extending venous thromboembolism secondary prevention with apixaban in cancer patients. The EVE trial","author":"McBane","year":"2024","journal-title":"J Thromb Haemost"},{"issue":"4","key":"10.1016\/j.lpm.2024.104242_bib0088","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1055\/a-1647-9896","article-title":"Extended anticoagulant treatment with full- or reduced-dose apixaban in patients with cancer-associated venous thromboembolism: rationale and design of the API-CAT study","volume":"122","author":"Mahe","year":"2022","journal-title":"Thromb Haemost"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498224000204?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498224000204?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T00:38:23Z","timestamp":1732667903000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0755498224000204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":88,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S0755498224000204"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2024.104242","relation":{},"ISSN":["0755-4982"],"issn-type":[{"value":"0755-4982","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preventative and curative treatment of venous thromboembolic disease in cancer patients","name":"articletitle","label":"Article Title"},{"value":"La Presse M\u00e9dicale","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2024.104242","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"104242"}}